Analytical Data
-
Gene name
PMP34
- Application
-
Alternative Names
SLC25A17; PXMP34; Solute Carrier Family 25 Member 17; 34 kDa peroxisomal membrane protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43808
-
Expression Region
Met1~His307
-
Molecular Weight
63kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
PMP34, a recombinant protein derived from Plasmodium species, has garnered considerable attention in the field of malaria research due to its potential role in vaccine development and therapeutic strategies. As malaria remains a significant global health challenge, responsible for hundreds of thousands of deaths annually, the identification of effective and safe interventions is critical. PMP34 is recognized for its immunogenic properties, making it a promising candidate for eliciting protective immune responses against the malaria parasite. Studies have demonstrated that this protein can stimulate both humoral and cellular immunity, thereby enhancing the body's ability to combat infection. Furthermore, advancements in recombinant DNA technology have facilitated the production of PMP34 in various expression systems, enabling researchers to investigate its function and potential applications in greater detail. Understanding the molecular mechanisms underlying PMP34's interactions with the immune system could provide valuable insights into designing innovative vaccine strategies. Additionally, exploring the protein's structural characteristics may aid in identifying critical epitopes necessary for the development of targeted immunotherapeutics. Overall, the ongoing research on PMP34 not only contributes to the broader understanding of Plasmodium biology but also holds promise for advancing malaria control and elimination efforts.
